Although no-link between inflammasome and liver problems have been described following CoV infections, previous studies have shown that inhibition of the NLRP3 inflammasome lowers the levels of ALT and AST, improving outcomes in liver fibrosis and non-alcoholic steatohepatitis (NASH) in mice (124), suggesting that inflammasome inhibition may be beneficial to control the effects caused by CoVs infections in the liver. This evidence concerns the gene GPT and Hepatic fibrosis.